Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor

Lancet. 1995 Apr 22;345(8956):1016-20. doi: 10.1016/s0140-6736(95)90757-2.


The idiotype of myeloma immunoglobulin can be used as a unique tumour-specific antigen. We tested the hypothesis that tumour antigen-specific immunity can be transferred from bone-marrow-transplant donor to recipient. We immunised a healthy sibling donor with myeloma immunoglobulin from the plasma of the recipient, conjugated to an immunogenic carrier protein and emulsified in an adjuvant, before marrow transplantation. Detection of a lymphoproliferative response, a parallel response in the carrier protein, recovery of a recipient CD4+ T-cell line with unique specificity for myeloma idiotype, and demonstration by in-situ hybridisation that the cell line was of donor origin, proved that a myeloma idiotype-specific T-cell response was successfully transferred to the recipient. Donor immunisation with myeloma idiotype may represent a new strategy for enhancing the specific anti-tumour effect of allogeneic marrow grafts.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Bone Marrow Transplantation*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Immunization, Passive*
  • Immunoglobulin Idiotypes / immunology*
  • In Situ Hybridization
  • Male
  • Middle Aged
  • Multiple Myeloma / immunology*
  • Multiple Myeloma / surgery*
  • T-Lymphocytes / immunology
  • Tissue Donors
  • Vaccination*


  • Immunoglobulin Idiotypes